Patient P-01516
Synthetic patientNBL-101 · Day 116 · 25–34 · M · baseline S13Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Improving
GI state
Deteriorating
Inflammatory state
Improving
Nutritional resilience
Favorable
Discontinuation risk
17%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S13
- Day 23 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 23.
Primary contributors, last 14 days
- Toxicity-12
- Inflammatory activity-10
- GI instability+4
- Treatment adherence+4
- Nutritional resilience-3
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion18.9/100
worsening · +3.1 vs previous 14 d
Toxicity
Blood7.7/100
improving · -4.0 vs previous 14 d
Sleep quality
Wearable58.8/100
worsening · -2.5 vs previous 14 d
Energy level
Daily log6/10
stable · -0.1 vs previous 14 d
Stress level
Daily log3.3/10
worsening · +0.2 vs previous 14 d
Steps
Wearable8,997
stable · -154 vs previous 14 d
Adherence
Companion86.7 %
worsening · -3.5 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 74 from the failing basin, 70 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More fatGI -2.1 next day on high-intake days · n 14
- More spicyGI -2 next day on high-intake days · n 19
Would not help
- Nothing clearly counter-productive in the record.
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Dietary fat load-2.1supporter · 60%
- Insoluble fibre+2.1no signal · 51%
- Spicy / capsaicin-2supporter · 57%
- Histamine load-0.8no signal · 21%
- Alcohol-0.4no signal · 15%
- Simple carbohydrates0no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Drug metabolism and exposure ↑35
- DNADPYD *2A → slower clearance
- Autonomic recovery ↓25
- WearableResting HR 75 bpm
DNA
Fictional pharmacogenomic panel
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3.8 · butyrate capacity 46/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 52 ms
- Sleep
- 6.4 h
- Steps
- 9,695
- Resting HR
- 73 bpm
Daily log: GI score 19, nutritional resilience 64, adherence 87.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01773 | 38% | S05 | AD-05 | improved | 27 |
| P-01731 | 33% | S01 | ME-01 | improved | 32 |
| P-01313 | 30% | S01 | BR-03 | improved | 32 |
| P-01320 | 28% | S09 | HY-01 | improved | 38 |
| P-01618 | 27% | S10 | GI-04 | improved | 39 |
| P-01374 | 25% | S08 | HY-01 | improved | 49 |
| P-01385 | 24% | S06 | HY-01 | improved | 50 |
| P-01861 | 24% | S12 | HY-01 | improved | 47 |
| P-01342 | 23% | S11 | DT-01 | improved | 48 |
| P-01346 | 23% | S12 | DT-01 | improved | 52 |
| P-01405 | 23% | S14 | SC-12 | improved | 44 |
| P-01752 | 23% | S20 | DT-01 | improved | 50 |